# **1** Acupuncture at Sanyinjiao(SP6) for patients with primary

# 2 dysmenorrhea: Protocol for a systematic review and

3

### meta-analysis

4 Xuemei Wang, PhD<sup>a</sup>, Jiao Yang, MS<sup>b</sup>, Jing Liu PhD<sup>a</sup>, YepengYang PhD<sup>c</sup>,

5 Zhiyuan Zhang, MS<sup>d</sup>, Ping Xie, BS<sup>a,\*</sup>

# 6 Author details

- <sup>a</sup>Department of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine; College of Clinical Medicine, Chengdu
  University of Traditional Chinese Medicine, Chengdu, Sichuan
  Province, P. R. China.
  <sup>b</sup>West China Second University Hospital, Sichuan University /West
  China women's and children's Hospital.
  <sup>c</sup>Shanxi University of Chinese Medicine.
- 14 <sup>d</sup>Dujiangyan Traditional Chinese Medicine Hospital, Chengdu, Sichuan
- 15 Province, P. R. China.
- 16 ORCID iD: Xuemei Wang
- 17 https://orcid.org/0000-0003-2108-1789
- 18 \*Correspondence: Ping Xie, Department of Gynecology, Hospital of

19 Chengdu University of Traditional Chinese Medicine, No. 39

- 20 Shi-er-qiao Road, Chengdu, 610072, Sichuan Province, P. R. China,
- 21 Email: <u>fxp2410@126.com</u>.

## 22 Funding

- 23 This study is funded by the National Science Foundation of China
- 24 (No. 82374512,81674017), http://www.nsfc.gov.cn/.

## 25 Competing interests

26 The authors have no conflicts of interest to disclose.

## 27 Availability of data and materials

- 28 After the completion of the systematic review, all the data extracted
- 29 from the literature will be published with the publication of the 30 article.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 31 Abstract

32	Background: Primary dysmenorrhea (PD) is a gynecological disease that
33	seriously affects women 's physical and mental health and quality of life.
34	Sanyinjiao (SP6) is the most used acupoint for acupuncture treatment of PD, and
35	acupuncture SP6 is more commonly used in the clinical treatment of PD, but
36	evidence of effectiveness and safety is lacking. The purpose of this systematic
37	review plan is to develop a study protocol that can evaluate the efficacy and
38	safety of acupuncture SP6 in the treatment of PD.
39	Methods: The upper limit of retrieval time will be set to September 2023.
40	Foreign and Chinese databases will be searched respectively: Cochrane Library,
41	PubMed, EMBASE, Ovid, Korea Med, J-Global, J-Stage databases, and CNKI,
42	CBM, SinoMed, VIP, Wanfang. Randomized controlled trials meeting the
43	inclusion criteria will be screened by two independent reviewers, and data
44	extraction and risk of bias assessment will be carried out. The primary outcome
45	is dysmenorrhea symptoms, and the secondary outcomes include recent clinical
46	cure rate, concomitant symptoms, serum prostaglandins, uterine artery blood
47	flow resistance under ultrasound monitoring, and adverse reactions. Use RevMan
48	V.5.3 software to perform the following operations: data synthesis, subgroup
49	analysis, heterogeneity analysis, and sensitivity analysis. The evidence quality of
50	clinical studies included in this study will be evaluated by the software of "
51	Grading of Recommendations Assessment, Development, and Evaluation ".

2

It is made available under a CC-BY-NC-ND 4.0 International license .

- 52 **Results:** This study will provide comprehensive clinical evidence for treating PD
- 53 with acupuncture SP6.
- 54 Conclusion: This systematic review will confirm whether acupuncture SP6 is safe
- 55 and effective in treating PD clinically.
- **56 Registration details:** PROSPERO CRD42020171664.
- 57 Abbreviations: PD = Primary Dysmenorrhea, SP6= Sanyinjiao, VAS = Visual
- 58 analogue scale, TCM = Traditional Chinese Medicine. LOCF=Last Observation
- 59 Carried forward, NSAIDs = Nonsteroidal Antiinflammatory Drugs, WCA =
- 60 Worst Case Analysis.
- 61 Keywords: acupuncture, sanyinjiao, SP6, primary dysmenorrhea, systematic review protocol

#### 62 **Background**

63 Primary dysmenorrhea (PD) manifests as the main symptoms of periodic lower 64 abdominal pain in women during or after menstruation, accompanied by other 65 discomforts, such as cold sweat, dizziness, nausea, vomiting, diarrhea, fatigue, 66 palpitation, etc., to affect work and life, and gynecological examination indicates 67 that there is no obvious organic disease in reproductive organs [1]. PD, a 68 common clinical gynecological disease, is most common in young unmarried 69 women and has a significant impact on women's health, life and work. It is also 70 the most common cause of absenteeism among women [2, 3]. PD is a huge 71 public health burden. The prevalence of PD reported abroad ranges from 34% to 72 94%, among which 61% are moderate dysmenorrhea [4]. A survey of 2000 female

It is made available under a CC-BY-NC-ND 4.0 International license .

adolescents shows that the prevalence of dysmenorrhea is 84.8% (n = 1080), the
average pain score is 5.87, about 34% (n = 439) of women have taken painkillers,
and the average absenteeism rate is 18%[5].

76 At present, the pathogenesis of primary dysmenorrhea is not completely 77 clear. It is generally believed that it is directly related to the increase of 78 prostaglandin, and it is also related to the secretion and synthesis of 79 vasopressin[6],  $\beta$ -endorphin[7], interleukin[8], oxytocin[9], estrogen, and 80 progesterone[10, 11]. Its comprehensive effect causes pathological contraction 81 of uterine smooth muscle, resulting in uterine ischemia and hypoxia, resulting in 82 dysmenorrhea [12, 13]. The commonly used drugs for clinical treatment of PD 83 are non-steroidal anti-inflammatory drugs (NSAIDs), antispasmodic drugs, 84 sedatives, contraceptive-based, the effect is exact [14]. However, these drugs can 85 only temporarily relieve pain, are not recommended for repeated use, and have 86 disadvantages such as limited efficiency and side effects. It is impossible to 87 carry out treatment for patients with no or low response to such drugs, treatment 88 contraindications, treatment intolerance, or non-acceptance.

Acupuncture is a common method of treating PD with traditional Chinese medicine (TCM), of which Sanyinjiao (SP6) is the most used acupoint. Acupuncture SP6 is widely used in the treatment of PD and is one of the alternative methods for the treatment of PD[15-17]. In addition, acupuncture has almost no side effects such as dizziness, headache, lethargy, gastrointestinal bleeding, and drug dependence. There is some mechanism of acupuncture SP6.

4

It is made available under a CC-BY-NC-ND 4.0 International license .

95 Acupoint SP6 is located on the inside of the ankle joint of human lower limbs 96 and is the intersection of the meridians of the liver, spleen, and kidney. 97 According to the theory of TCM, the main pathogenesis of PD is the imbalance 98 of Chongren and blocked meridians. Acupuncture SP6 has the functions of 99 regulating Chongren, dredging collaterals, and relieving pain. Although the 100 mechanism of acupuncture SP6 in the treatment of PD has not been fully 101 elucidated. However, animal experiments show that acupuncture SP6 can play a 102 role through the following mechanisms [18]: (1) improving uterine 103 microcirculation disturbance; (2) regulate the endocrine function; (3) improve 104 the function of the immune system; (4) affect the metabolism of nerve and 105 neurotransmitters.

106 In 2013, a systematic review of acupuncture SP6 for PD, the experimental 107 group and control group were acupuncture SP6 and GB39, respectively. The 108 outcome index was only related to the visual analog scale (VAS) pain score. This 109 study failed to evaluate the efficacy, improvement of accompanying symptoms, 110 adverse reactions, and safety of acupuncture SP6 for PD. Acupuncture is widely 111 used in East Asia, represented by China, Japan, and Korea. However, in this 112 study, only four English databases were retrieved, not East Asian databases. 113 Therefore, there are some imperfections in the design of the systematic review, 114 which may affect the authenticity of its research results. In recent years, the 115 clinical research of acupuncture SP6 in the treatment of PD has gradually 116 increased, and the efficacy evaluation indicators have also gradually increased

It is made available under a CC-BY-NC-ND 4.0 International license .

117 [15, 19, 20]. Therefore, the aim of this systematic review is to evaluate the
118 efficacy and safety of acupuncture at SP6 in the treatment of PD. This work will
119 provide reliable clinical evidence with objective results by formulating strict
120 retrieval strategies and standardized research programs.

#### 121 Methods

### 122 **Registration and ethics**

123 This systematic review protocol has been registered on PROSPERO international 124 platform with the registration number CRD 42020171664 125 (https://www.crd.york.ac.uk/PROSPERO/). In the process of implementation, 126 this work will strictly refer to the detailed rules [17] and specifications set in the 127 statement of Preferred Reporting Items for Systematic Reviews and 128 meta-analyses (PRISMA) [18, 21, 22]. This protocol is designed to guide further 129 systematic review work, so there is no need for ethical review. Extracting 130 relevant data from published literature will be the source of data needed in this 131 systematic review, and the process of using literature data does not involve 132 ethical issues.

#### 133 Studies of eligibility criteria

**Types of studies design.** We will include randomized controlled trials (RCTs)
of acupuncture at SP6 points for PD. The included studies will not consider the
restrictions of region, publishing language, publishing status, and publishing
year. Non-randomized controlled trials, literature reviews, animal experiments,

It is made available under a CC-BY-NC-ND 4.0 International license .

138 case reports, medical record discussions, experience summaries, and theoretical139 discussions will be excluded.

140 Participants. According to the clinical practice guidelines for primary 141 dysmenorrhea issued by SOGC [18, 23], this study will include patients who 142 meet the diagnostic criteria for primary dysmenorrhea. The diagnostic criteria of 143 PD include periodic lower abdominal pain during menstruation or before and 144 after menstruation (within 1 week), sometimes accompanied by soreness of the 145 waist, fatigue, nausea, vomiting, cold limbs, and other discomforts, which affects 146 work and life. After gynecological examination, there is no obvious organic 147 lesion in reproductive organs. This disease mostly occurs in adolescent girls 2 to 148 3 years after menarche or young women who have not given birth. Regardless of 149 race, nationality, education level, and economic status of patients.

150 Types of interventions. We will include clinical trials of acupuncture at SP6
151 for PD, excluding those using other methods (acupoint injection, acupoint catgut
152 embedding, acupressure, moxibustion, cupping, transcutaneous electrical nerve
153 stimulation) to stimulate SP6 for PD.

154 The control group can be SP6 sham acupuncture, placebo, blank group. 155 Studies in which the control group consisted of drug therapy (eg, NSAIDs, 156 Hormonal Treatment, vitamins), acupoint injections, and other 157 complementary alternative therapies (eg, Chinese herbal medicine, yoga, 158 Dietary Supplements) will be excluded. The following treatment comparisons

7

It is made available under a CC-BY-NC-ND 4.0 International license .

- 159 will be considered. (1) SP6 acupuncture / SP6 sham acupuncture; (2) SP6
- acupuncture / placebo; (3) SP6 acupuncture / no treatment.
- 161 Outcome measures

162 Primary outcome. The primary outcome will be the Pain index. Visual163 analogue scale (VAS) to assess changes in pain intensity.

Secondary outcome. (1) The recent clinical recovery rate. After treatment,
abdominal pain and other symptoms disappeared, and no recurrence occurred
in 3 menstrual cycles. (2) indicators of concomitant symptoms. Concomitant
symptoms were evaluated by the following scales: Cox menstrual symptom
scale (CMSS), menstrual symptom score (MSS), retrospective symptom scale
(RSS). (3) Serum prostaglandin. (4) Ultrasonic monitoring of uterine artery
blood flow resistance. (5) Adverse reactions, adverse events.

171 Literature sources and retrieval strategies

172 General database retrieval and retrieval strategy Electronic databases 173 will be searched to obtain the required study literature. The upper limit of 174 retrieval time will be set to September 2023. Foreign and Chinese databases will 175 be searched respectively: Cochrane Library, PubMed, EMBASE, Ovid, Korea 176 Med, J-Global, J-Stage databases, and CNKI, CBM, SinoMed, VIP, Wanfang. 177 Randomized controlled trials meeting the inclusion criteria will be screened by 178 two independent reviewers (XW, JY). We will search the above 12 databases 179 using subject terms and free words. The retrieval strategy of the PubMed 180 database is shown in Table 1, and the retrieval strategies of other databases need

It is made available under a CC-BY-NC-ND 4.0 International license .

- 181 to be converted accordingly. For the related studies involved in the references,
- 182 manual retrieval will be adopted.
- 183 Table 1. Search strategy for PubMed.

Number	Search terms of query
#1	Dysmenorrhea[Mesh] OR Functional dysmenorrhea[tiab] OR
	Primary dysmenorrhea [tiab] OR algomenorrhea[tiab] OR
	menalgia[tiab] OR menorrhalgia*[tiab] OR Menstruation
	Disturbances[Mesh] OR difficult menstruation [tiab]
#2	Menstrua*[tiab]OR Menses[tiab]
#3	Colic[Mesh] OR Cramp*[tiab] OR Pain*[tiab]
#4	#2 AND #3
#5	#1 OR #4
#6	Acupuncture therapy [Mesh] OR Acupuncture[tiab]
#7	Sanyinjiao[tiab] OR SP6[tiab]
#8	Acupuncture Points[Mesh] OR *Point*[tiab]
#9	#7 and #8
#10	#5 and #6 and #9
#11	randomized controlled trial[pt] OR controlled clinical
	trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical
	trials as topic [Mesh: NoExp] OR randomly[tiab] OR
	trial[tiab]) NOT (animals[Mesh] NOT humans [Mesh])
#12	#10 and #11

184

185 Other database resources To obtain data from ongoing clinical trials, the
186 following databases will be searched: UK National Research Register, WHO
187 ICTRP, ISRCTN, UK Clinical Trial Gateway, Clinic-Trials.gov, UMIN CTR,
188 Chinese Clinical Trial Register. To obtain unpublished clinical trial data, we will
189 continue to search the following databases: OpenGrey, ProQuest, and Conference

190 Literature Database ISI proceeding.

### **191 Data extraction and analysis**

192 Study selection Two independent reviewers (JL, ZZ) will be responsible for

- 193 the literature screening, and the bibliographies that qualified in the preliminary
- 194 screening will be imported into the literature management software EndNote (V.
- 195 X9.0). and then read the titles and abstracts one by one, and eliminate the

It is made available under a CC-BY-NC-ND 4.0 International license .

196	duplicate or unqualified literature titles. After obtaining the full text of the
197	bibliography, read the full text carefully and evaluate the final included
198	literature according to the inclusion criteria. For the literature that did not meet
199	the inclusion criteria, Excel will be used to record the reasons for exclusion in
200	detail. If the full text is not available in the database, we will contact the
201	corresponding author via email to obtain the full text. If there is a disagreement
202	in the whole process of literature screening, the third reviewer (PX) will help to
203	judge. The process of study screening is shown in the flowchart (Fig 1).

204 Figure1: The PRISMA flow diagram of literature screening process.

Figure 1 see attachment.

206 Data extraction The contents of the Excel spreadsheet used for literature 207 data extraction will be decided after discussion by all authors. The contents of 208 the data extraction Excel are composed of five parts: basic information (number, 209 title, author, year, journal, country, fund, language); Study methods (diagnostic 210 criteria, sample size, design type, statistical method, randomized method, 211 treatment plan concealment, blind method, study data integrity, follow-up time); 212 Patient characteristics (course of disease, degree of dysmenorrhea, age, region); 213 Intervention measures (treatment frequency, treatment time, acupuncture 214 group/control group type); Outcome indicators (outcome measurement methods, 215 measurement time points, primary outcome indicators, secondary outcome 216 indicators, efficacy evaluation methods, adverse reactions).

It is made available under a CC-BY-NC-ND 4.0 International license .

217 Before the formal literature data extraction, the applicability of the 218 literature extraction form will be tested, and the literature extraction form will be 219 modified according to the preliminary test results to make it more perfect and 220 reliable. Two uniformly trained reviewers (ZZ, JY) will be responsible for 221 formal literature data extraction. If there are differences in the process of data 222 extraction, the two authors will discuss and solve them first. If differences still 223 exist after discussion, the third reviewer (PX) will assist in judging. In the 224 process of data extraction, if the data records are fuzzy and difficult to be 225 extracted, we will contact the corresponding author via e-mail and confirm the 226 data. After data extraction, two reviewers (YY, PX) will cross-check the 227 extraction results and input them into Revman software (V.5.3).

228 Risk of bias assessment Two reviewers (JY, YY) will carefully read the 229 specific requirements of Cochrane Review Handbook 5.1.0 [18, 19] for bias risk 230 assessment, and will independently use the Cochrane Risk-Of Bias [24] 231 assessment tool to evaluate the risk of bias of the included studies. After the 232 assessment, the two reviewers will cross-check the assessment results. If the 233 assessment results of both parties are different, they will be discussed and 234 resolved through negotiation first. If the differences cannot be resolved after 235 discussion, the third author (XW) shall assist in the judgment. We will evaluate 236 the risk of bias in terms of the method of random sequence generation, whether 237 the allocation scheme is hidden, whether participants are blinded, whether the 238 study outcome evaluation is blinded, the integrity of the outcome data, selective

It is made available under a CC-BY-NC-ND 4.0 International license .

reporting, and so on. Bias risk assessment results are divided into three
categories: high risk, low risk, and unclear. The assessment results will be
imported into Review Manager 5.3 software to generate the risk of bias graph
and risk of bias summary.

Measures of treatment effect. If the study results are dichotomous data, we will use odds ratio (OR) and 95% confidence interval (CI) to evaluate the efficacy of acupuncture SP6 in treating PD. If the study results are continuous data, we will evaluate the curative effect of acupuncture SP6 on PD using mean difference (MD), or standardized mean difference (SMD), and 95% confidence interval (CI).

249 Dealing with missing data. If the record of study data is not integrity, we will 250 contact the corresponding author through e-mail, telephone, etc., to obtain 251 complete study data as far as possible. If the complete data is still not available, 252 the research team members will exclude this study after discussion. The impact 253 of missing data on the overall study results will be determined by sensitivity 254 analysis.

Assessment of heterogeneity. The heterogeneity among all included studies will be measured by the Chi-square test ( $\chi 2$ ) and I<sup>2</sup> test. If the heterogeneity among the included studies is low, that is, P > 0.1 and I<sup>2</sup> ≤50%, the fixed-effect model should be used to analyze the study results. If the heterogeneity among the included studies is moderate, that is, P≤0.1 and I<sup>2</sup> > 50%, the random effect model should be used to analyze the study results. If the heterogeneity among the

It is made available under a CC-BY-NC-ND 4.0 International license .

included studies is high, that is,  $P \le 0.1$ ,  $I^2 > 75\%$ , subgroup analysis or descriptive analysis should be conducted.

Analysis of publication bias. If the total number of studies finally included in this systematic review exceeds 10, we will use a funnel plot to evaluate publication bias. If necessary, we will further use the Egger regression and Begg correlation test to test the symmetry of the funnel plot. In addition to publication bias, selectivity bias, language bias, and citation bias may also lead to funnel plot asymmetry. If there is an asymmetry in the funnel plot, we will try to analyze the reasons.

270 Data synthesis The study data will be synthesized and analyzed using 271 RevMan5.3 software according to Cochrane guidelines. If the heterogeneity 272 among the included studies is low, the fixed-effect model should be used to 273 analyze the study results. If the heterogeneity among the included studies is 274 moderate, the random effect model should be used to analyze the study results. If 275 the heterogeneity among the included studies is high, subgroup analysis or 276 descriptive analysis should be conducted.

#### 277 Subgroup analysis

If the analysis of heterogeneity indicates that there is a certain degree of heterogeneity among the studies included in this systematic review, we will use subgroup analysis to determine the source of the heterogeneity. In this study, subgroup analysis can be performed in terms of patient age, depth of acupuncture, frequency of acupuncture, and duration of illness.

It is made available under a CC-BY-NC-ND 4.0 International license .

283 Sensitivity analysis The stability of systematic review results can be tested
284 by sensitivity analysis. We will test the stability of meta-analysis results from
285 the aspects of literature quality, sample size, data integrity, and so on.

286 Grading of evidence quality According to the detailed requirements of the 287 quality of evidence in clinical studies in GRADE guidelines and the 288 classification of the quality of evidence: high, moderate, low, or very low. We 289 will use the GRADE software to evaluate the quality of evidence in clinical 290 studies included in this systematic review.

#### 291 **Discussion**

292 It is recorded in ancient books of traditional Chinese medicine that SP6 point 293 is good at treating dysmenorrhea, and the clinical application of acupuncture 294 at SP6 in the treatment of PD has gradually increased in clinical practice. 295 Chinese experts agree that acupuncture can be used as an adjunct or 296 alternative to PD therapy [25]. However, 2017 SOGC Clinical Practice 297 Guideline (No. 345-Primary Dysmenorrhea ConsensusGuideline) states that 298 there is insufficient evidence to support the efficacy and safety of 299 acupuncture at SP6 in the treatment of PD, therefore, we conducted a 300 systematic review and meta-analysis to evaluate the efficacy and safety of 301 acupuncture at Sanyinjiao point in the treatment of PD patients. There are 302 inevitable limitations to this systematic review. First, there may be a risk of 303 heterogeneity in the way of acupuncture, the type of needle, and the duration 304 of a single acupuncture treatment, and second, it is difficult to obtain

It is made available under a CC-BY-NC-ND 4.0 International license .

305	complete raw data from the literature, which may cause reporting bias, which
306	we will clarify in detail. It is hoped that this study will provide the latest
307	evidence analysis on the effectiveness of acupuncture at SP6 in the treatment
308	of PD in order to provide ideas and methods that can be used for reference for
309	doctors, patients, and medical policy-makers.
310	Supporting information
311 312	S1 Checklist. PRISMA-P 2015 Checklist (DOCX)
313	Author contributions
314	Conceptualization: Xuemei Wang, Ping Xie.
315	Data curation: Xuemei Wang, Jiao Yang, Zhiyuan Zhang.
316	Formal analysis: Xuemei Wang, Jing Liu, YepengYang.
317	Funding acquisition: Ping Xie.
318	Investigation: Xuemei Wang, Jiao Yang, Zhiyuan Zhang.
319	Methodology: Xuemei Wang, Jing Liu, YepengYang.
320	Project administration: Xuemei Wang, Ping Xie.
321	Resources: Xuemei Wang, Jiao Yang, Zhiyuan Zhang.
322	Software: Xuemei Wang, Jing Liu, YepengYang.
323	Supervision: Xuemei Wang, Jiao Yang, Ping Xie.
324	Validation: Xuemei Wang, Ping Xie.
325	Visualization: Xuemei Wang, Ping Xie.
326	Writing – original draft: Xuemei Wang.
327	Writing – review & editing: Ping Xie. 15

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 328 Acknowledgements

- 329 This work is supported by the National Science Foundation of China
- **330** (No. 82374512,81674017).

#### 331 Ethics approval and consent to participate

- 332 This work is a systematic review and does not need to be submitted
- 333 to the ethics committee for review.

### 334 **Consent for publication**

335 Our research results will be published in peer-reviewed scientific

journals, the Prospero website, and relevant academic conferences.

#### 337 **References**

- 338 1. Chen BL, Guo Q, Zhang QW, Di Z, Zhang QA. Revealing the Central Mechanism of
- 339 Acupuncture for Primary Dysmenorrhea Based on Neuroimaging: A Narrative Review. Pain
- 340 research & management. 2023;2023. <u>https://doi.org/10.1155/2023/8307249</u> PMID:
- **341** WOS:000938131200001.
- 342 2. Mammo M, Alemayehu M, Ambaw G. Prevalence of Primary Dysmenorrhea, Its
- 343 Intensity and Associated Factors Among Female Students at High Schools of Wolaita Zone,
- 344 Southern Ethiopia: Cross-Sectional Study Design. International Journal of Womens Health.
- 345 2022;14:1569-77. <u>https://doi.org/10.2147/IJWH.S384275</u> PMID: WOS:000885490800001.
- 346 3. Ortiz MI. The Trend of Increasing Primary Dysmenorrhea Prevalence in Mexican
- 347 University Students. Clinical and Experimental Obstetrics & Gynecology. 2023;50(3).
  348 https://doi.org/10.31083/j.ceog5003058 PMID: WOS:000975453700015.
- 349 4. Azagew AW, Kassie DG, Walle TA. Prevalence of primary dysmenorrhea, its intensity,
- 350 impact and associated factors among female students' at Gondar town preparatory school,
- 351 Northwest Ethiopia. BMC women's health. 2020;20(1):5. Epub 2020/01/08.
- 352 <u>https://doi.org/10.1186/s12905-019-0873-4</u> PMID: 31906945; PubMed Central PMCID:
   353 PMCPMC6945628.
- 354 5. Yucel G, Kendirci M, Gul U. Menstrual Characteristics and Related Problems in 9- to
- 355 18-Year-Old Turkish School Girls. Journal of pediatric and adolescent gynecology.
- **356** 2018;31(4):350-5. Epub 2018/03/20. <u>https://doi.org/10.1016/j.jpag.2018.03.002</u> PMID:
- **357** 29550626.
- **358** 6. Oladosu FA, Tu FF, Garfield LB, Garrison EF, Steiner ND, Roth GE, et al. Low Serum
- 359 Oxytocin Concentrations Are Associated with Painful Menstruation. Reproductive sciences
- 360 (Thousand Oaks, Calif). 2020;27(2):668-74. Epub 2020/02/13.

It is made available under a CC-BY-NC-ND 4.0 International license .

361	https://doi.org/10.1007/s43032-019-00071-y PMID: 32046441; PubMed Central PMCID:
362	PMCPMC7044072.
363	7. Libarle M, Simon P, Bogne V, Pintiaux A, Furet E. [Management of dysmenorrhea].
364	Revue medicale de Bruxelles. 2018;39(4):264-72. Epub 2018/10/16. PubMed PMID:
365	30320987.
366	8. Barcikowska Z, Rajkowska-Labon E, Grzybowska ME, Hansdorfer-Korzon R, Zorena K.
367	Inflammatory Markers in Dysmenorrhea and Therapeutic Options. International journal of
368	environmental research and public health. 2020;17(4). Epub 2020/02/20.
369	https://doi.org/10.3390/ijerph17041191 PMID: 32069859.
370	9. Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. American
371	family physician. 2014;89(5):341-6. Epub 2014/04/04. PubMed PMID: 24695505.
372	10. Yang WW, Chen PB, Jin LM, Tang XY, Qin ZY, Zhou YJ, et al. [Effect of proximal and
373	distal acupoint catgut-embedding on uterus prostaglandin, serum IL-2 and splenic NK cell
374	activity in primary dysmenorrhea rats]. Zhen Ci Yan Jiu. 2021;46(3):221-5. Epub 2021/04/03.
375	https://doi.org/10.13702/j.1000-0607.200618 PMID: 33798295.
376	11. Woo HL, Ji HR, Pak YK, Lee H, Heo SJ, Lee JM, et al. The efficacy and safety of
377	acupuncture in women with primary dysmenorrhea: A systematic review and meta-analysis.
378	Medicine (Baltimore). 2018;97(23):e11007. Epub 2018/06/08.
379	https://doi.org/10.1097/md.000000000011007 PMID: 29879061; PubMed Central PMCID:
380	PMCPMC5999465.
381	12. Zhang F, Sun M, Han S, Shen X, Luo Y, Zhong D, et al. Acupuncture for Primary
382	Dysmenorrhea: An Overview of Systematic Reviews. Evid Based Complement Alternat Med.
383	2018;2018:8791538. Epub 2018/12/26. https://doi.org/10.1155/2018/8791538 PMID:
384	30584456; PubMed Central PMCID: PMCPMC6280308.
385	13. Afshari Fard MR, Mohammadi A, Ma LX, Mu JD, Yu WY, Song Y, et al. Comparison
386	of the immediate analgesic effect of perpendicular needling and transverse needling at SP6 in
387	patients with primary dysmenorrhea: Study protocol for a randomized controlled trial.
388	Medicine (Baltimore). 2020;99(3):e18847. Epub 2020/02/06.
389	https://doi.org/10.1097/md.00000000018847 PMID: 32011502; PubMed Central PMCID:
390	РМСРМС7220365.
391	14. Yongxia W, Siyi Y, Hong Z, jie Y. Mechanism R esearch on Treatment of Primary
392	Dysmenorrhea with Acupuncture and Moxibustion of Sanyinjiao (SP6). Journal of Chengdu
393	University of TCM. 2015;38(04):106-8. Epub 2015/12/15.
394	https://doi.org/10.13593/j.cnki.51-1501/r.2015.04.106
395	15. Sun J, Wang Y, Zhang Z, Cao H, Wang P, Zhao M, et al. [Efficacy of filiform needle
396	manipulation on primary dysmenorrhea:a systematic review]. Zhongguo zhen jiu = Chinese
390 397	acupuncture & moxibustion. 2017;37(8):887-92. Epub 2017/12/13.
398	https://doi.org/10.13703/j.0255-2930.2017.08.023 PMID: 29231353.
399 399	<ol> <li>Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline. Journal of</li> </ol>
400	obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada :
401	JOGC. $2017;39(7):585-95$ . Epub $2017/06/20$ . <u>https://doi.org/10.1016/j.jogc.2016.12.023</u>
TUT	JOGC. 2017, 59(7). 365-95. Epud 2017/00/20. <u>https://doi.org/10.1010/j.jogc.2010.12.025</u>


402 PMID: 28625286.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 403 17. Shamseer L, Moher D, M. C. Preferred reporting items for systematic review and
- 404 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical
- 405 research ed). 2016;354:i4086. Epub 2016/07/23. <u>https://doi.org/10.1136/bmj.i4086</u> PMID:
- 406 27444514.
- 407 18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The
- 408 PRISMA statement for reporting systematic reviews and meta-analyses of studies that
- 409 evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed).
- 410 2009;339:b2700. Epub 2009/07/23. <u>https://doi.org/10.1136/bmj.b2700</u> PMID: 19622552;
- 411 PubMed Central PMCID: PMCPMC2714672.
- 412 19. Higgins JP. Cochrane handbook for systematic reviews of interventions. Version 5.1.0
- 413 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbookorg. 2011.
- 414 20. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane
- 415 Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed).
- 416 2011;343:d5928. Epub 2011/10/20. <u>https://doi.org/10.1136/bmj.d5928</u> PMID: 22008217;
- 417 PubMed Central PMCID: PMCPMC3196245.
- 418 21. Barcot O, Boric M, Poklepovic Pericic T, Cavar M, Dosenovic S, Vuka I, et al. Risk of
- 419 bias judgments for random sequence generation in Cochrane systematic reviews were
- 420 frequently not in line with Cochrane Handbook. BMC medical research methodology.
- 421 2019;19(1):170. Epub 2019/08/07. <u>https://doi.org/10.1186/s12874-019-0804-v</u> PMID:
- 422 31382898; PubMed Central PMCID: PMCPMC6683577.
- 423 22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- 424 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS
- 425 medicine. 2021;18(3). <u>https://doi.org/10.1371/journal.pmed.1003583</u> PMID:
- 426 WOS:000636251100003.
- 427 23. Tu F, Hellman K. Primary Dysmenorrhea: Diagnosis and Therapy. Obstetrics and
- 428 gynecology. 2021;137(4):752. Epub 2021/03/25.
- 429 <u>https://doi.org/10.1097/aog.0000000004341</u> PMID: 33759824; PubMed Central PMCID:
   430 PMCPMC8034604.
- 431 24. Aamann L, Dam G, Rinnov AR, Vilstrup H, Gluud LL. Physical exercise for people with
- 432 cirrhosis. The Cochrane database of systematic reviews. 2018;12:Cd012678. Epub
- 433 2018/12/24. <u>https://doi.org/10.1002/14651858.CD012678</u> PMID: 30575956; PubMed Central
- **434** PMCID: PMCPMC6517144.
- 435 25. Zhang JJ, Wang J, Bai P, Tan C, Wang ZC, Chen S, et al. [Evidence-based Clinical
- 436 Practice Guideline of Acupuncture and Moxibustion for Primary Dysmenorrhea: development
- 437 and characteristics]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion.
- 438 2019;39(12):1343-6. Epub 2019/12/11. https://doi.org/10.13703/j.0255-2930.2019.12.023
- **439** PMID: 31820613.
- 440
- 441
- 442
- 443
- 444
- 445

It is made available under a CC-BY-NC-ND 4.0 International license .

446 Figure1: The PRISMA flow diagram of literature screening process.



*From:* Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

Figure 1. The PRISMA flow diagram of literature screening process.